Interference with ERK and STAT signaling pathways and inhibition of hepatitis C virus replication by ribavirin

Area of Science:

• Hepatology
• Virology
• Molecular Biology
• Immunology

Background:

• Hepatitis C virus (HCV) infection is a significant global health concern, with ribavirin and interferon-alpha (IFN-α) being the standard treatment.
• Ribavirin's antiviral activity is known to involve interference with cellular signaling pathways, but the specific pathways affected by ribavirin during HCV infection remain largely uncharacterized.
• Understanding these signaling events is crucial for elucidating the mechanism of action of ribavirin and potentially developing more effective therapies.

Purpose of the Study:

• To investigate the effects of ribavirin on the extracellular signal-regulated kinase (ERK) and signal transducers and activators of transcription (STAT) signaling pathways in HCV-infected human hepatoma cells.
• To evaluate the impact of ribavirin on HCV replication and the expression of antiviral genes.
• To explore the synergistic interactions between ribavirin and IFN-α on these signaling pathways and viral replication.

Main Methods:

• Human hepatoma cells were infected with cell culture-derived HCV.
• The effects of ribavirin, alone and in combination with IFN-α, on the phosphorylation status of key proteins in the ERK (Raf, MEK, ERK) and STAT (Tyk2, STAT1, STAT3) pathways were assessed.
• HCV RNA replication, HCV protein expression, and the expression of interferon regulatory factors (IRF9) and interferon-stimulated genes (ISG15) were quantified.

Main Results:

• Ribavirin reduced the phosphorylation of Raf, MEK, ERK, Tyk2, and STAT1, while selectively increasing STAT3 phosphorylation in HCV-infected cells.
• IFN-α showed synergistic effects with ribavirin on ERK and STAT3 phosphorylation and enhanced STAT1 expression and phosphorylation.
• Ribavirin demonstrated a dose-dependent inhibition of HCV RNA replication and protein expression, with minor induction of IRF9 and ISG15. A synergistic inhibitory effect on HCV was observed with the combination of ribavirin and IFN-α.

Conclusions:

• Ribavirin interferes with the ERK and STAT signaling pathways in HCV-infected cells, suggesting these pathways are involved in its anti-HCV mechanism.
• The combination of ribavirin and IFN-α exhibits synergistic antiviral activity against HCV, partly through modulation of ERK and STAT signaling.
• These findings provide insights into the molecular mechanisms underlying ribavirin's efficacy against HCV and highlight the importance of signaling pathway modulation in antiviral therapy.